Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 5/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7235002 | 0.81 | CYP2A6 (0.40) | CYP2A6ERN1 | |
| SCHEMBL5539648 | 0.79 | CYP2A6 (0.38) | CYP2A6MEN1KMT2ATDP1LMNA | |
| SCHEMBL6975978 | 0.76 | CYP2A6 (0.44) | CYP2A6ERN1ALDH1A1TSHRKDM4E | |
| SCHEMBL4444860 | 0.73 | CYP2A6 (0.44) | CYP2A6MEN1KMT2ATDP1LMNA | |
| SCHEMBL28548352 | 0.73 | CYP2A6 (0.48) | CYP2A6MEN1KMT2ATDP1LMNA | |
| SCHEMBL16353758 | 0.73 | RXRA (0.57) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL16353759 | 0.73 | RXRA (0.57) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL9112211 | 0.73 | CYP2A6 (0.34) | CYP2A6ADRA2AADRA2BCYP19A1TBXAS1 | |
| SCHEMBL3617335 | 0.73 | NFE2L2 (0.48) | CYP2A6KDM4E | |
| SCHEMBL3617338 | 0.73 | NFE2L2 (0.48) | CYP2A6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994580-A | High refractive index polymer material containing sulfur and selenium element and preparation method thereof | 吉林大学 | 2024-11-22 | — | — | CN | claimed |
| US-20250270210-A1 | BCL-2 Inhibitor | BEIGENE, LTD. (KY) | 2025-08-28 | — | — | US | disclosed |
| US-12286430-B2 | Bcl-2 inhibitor | BEIGENE, LTD. (KY) | 2025-04-29 | — | — | US | disclosed |
| CN-118994580-A | High refractive index polymer material containing sulfur and selenium element and preparation method thereof | 吉林大学 | 2024-11-22 | — | — | CN | disclosed |
| US-20240376097-A1 | BCL-2 Inhibitor | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| CN-116969937-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969936-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023201012-A1 | IKZF2 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-19 | — | — | WO | disclosed |
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-111285808-B | 4-aromatic heterocycle substituted indazole compound and application thereof as IDO/TDO dual inhibitor | 西华大学 | 2023-06-23 | — | — | CN | disclosed |
| EP-1555257-A1 | PROCESS FOR PRODUCING AROMATIC NITRILE COMPOUND | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6797726-B1 | N-alkoxyalkyl-N,N-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1047664-B1 | NOVEL TRICYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2004-05-19 | — | — | EP | disclosed |
| US-6423870-B1 | ANTICOAGULANTS; CIRCADIAN RHYTHM DISORDERS; SLEEP DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-07-23 | — | — | US | disclosed |
| EP-1186594-A1 | N-ALKOXYALKYL-N,N-DIALKYLAMINE DERIVATIVES OR SALTS THEREOF, AND REMEDIES FOR NERVE DEGENERATION DISEASES CONTAINING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-03-13 | — | — | EP | disclosed |
| US-5340833-A | Antiarthritic, antiinflammatory, antitumor agents | EISAI CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0568289-A2 | Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors | Eisai Co., Ltd. (JP) | 1993-11-03 | — | — | EP | disclosed |
| EP-0125059-B1 | HERBICIDAL CYCLOHEXANE-1,3-DIONE DERIVATIVES | ICI AUSTRALIA LIMITED (AU) | 1991-02-27 | — | — | EP | disclosed |
| US-4664693-A | POSTEMERGENCE | ICI AUSTRALIA LIMITED (AU) | 1987-05-12 | — | — | US | disclosed |
| EP-0125059-A2 | Herbicidal cyclohexane-1,3-dione derivatives | ICI AUSTRALIA LIMITED (AU) | 1984-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270210-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | CYP2A6 3337/4885MEN1 4022/4885KMT2A 2445/4885 |
| US-20240376097-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | CYP2A6 3337/4885MEN1 4022/4885KMT2A 2445/4885 |
| US-12286430-B2 | Bcl-2 inhibitor | BCL2, BCL2A1, BCL2L1 | CYP2A6 3337/4885MEN1 4022/4885KMT2A 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.